Stereotactic Body Radiotherapy for Large (&gt; 5 cm) Non–Small-Cell Lung Cancer

Peterson, Justin; Niles, Christian; Patel, Ashish; Boujaoude, Ziad; Abouzgheib, Wissam; Goldsmith, Ben; Asbell, Sucha O.; Xu, Qiang; Khrizman, Polina; Kubicek, Gregory J.

doi:10.1016/j.cllc.2016.11.020

Cited by 29 publications

(21 citation statements)

References 16 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26 Four recently published articles describing SABR for lung tumors larger than 5 cm reported similar median survival times (17.5-25.1 months) (Supplementary Table 1). [5][6][7][8] Grade 3 or higher toxicity was reported in 7.5% or less of patients after a median follow-up of 15 months or less. The relatively short follow-up in some reports may be relevant, as 42% of severe toxicity observed in our patients manifested after 12 months.…”

Section: Discussionmentioning

confidence: 99%

“…[2][3][4] Because of the limited data available on toxicity of SABR, conventional radical radiotherapy schemes have been recommended by the European Society for Medical Oncology for lesions larger than 5 cm. 1,[5][6][7][8] Lung SABR was introduced at our institution in 2003, with good disease control and limited treatment toxicity reported. [9][10][11] Improvements in treatment planning and delivery have enabled better sparing of normal organs, leading to an increased use of SABR for tumors exceeding 5 cm.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Use of Stereotactic Ablative Radiotherapy (SABR) in Non–Small Cell Lung Cancer Measuring More Than 5 cm

Tekatli

Hof

Nossent

et al. 2017

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Use of Stereotactic Ablative Radiotherapy (SABR) in Non–Small Cell Lung Cancer Measuring More Than 5 cm

Tekatli

Hof

Nossent

et al. 2017

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

“…5×10 3 /well A549, A549/DDP, PC9, and PC9/DDP cells were inoculated into 96 well plates for 12 h, then, the different concentrations of delicaflavone (5,10,20,40 and 80 µM) or DDP (2,4,8,16 and 32 µM) were added. In the meantime, A549/DDP cells were cultured with delicaflavone (20 µM) or DDP (16 µM) or delicaflavone (20 µM)+DDP (16 µM).…”

Section: Cck8 Analysismentioning

confidence: 99%

<p>Delicaflavone Reverses Cisplatin Resistance via Endoplasmic Reticulum Stress Signaling Pathway in Non-Small Cell Lung Cancer Cells</p>

Wang

Chen

et al. 2020

OTT

View full text Add to dashboard Cite

Background: The incidence and mortality of lung cancer continue to increase around the world; in 2018, new lung cancer cases accounted for 11.6% of all cancer cases, and lung cancer deaths accounted for 18.4% of cancer deaths. Cisplatin (DDP) is a first-line chemotherapy drug for lung cancer; however, DDP resistance can lead to a poor prognosis in patients with lung cancer. Therefore, reversing DDP resistance is a treatment goal. Materials and Methods: Cell counting kit-8 (CCK8) assays, wound healing analyses, Transwell assays, in vitro tumor xenografts, and flow cytometry were used to detect the proliferation, migration, invasion, and apoptosis of multidrug resistant A549/DDP and PC9/ DDP cells, respectively. Western blot was performed to detect protein levels of cleaved caspase-3, CHOP, and GRP78. Results: Delicaflavone inhibited DDP resistance of lung cancer cells and decreased proliferation in a dose-and time-dependent manner. It also decreased migration and invasion and enhanced apoptosis. Western blots showed that delicaflavone overcame DDP resistance by increasing the expression of GRP78 and CHOP and the apoptosis-related protein cleaved caspase-3. Conclusion: Delicaflavone can reverse DDP resistance in A549/DDP and PC9/DDP cells by inhibiting cell proliferation and migration and enhancing apoptosis and cleaved caspase-3 levels by increasing the expression of CHOP and GRP78 protein via the endoplasmic reticular stress pathway. It could be a useful therapeutic adjunct to treat DDP-resistant lung cancer.

show abstract

“…A report of 41 patients was published from Cooper University Hospital (31). Sixty-three percent of lesions were central, with the median RT dose and fractionation of 50 Gy in 5 fractions.…”

Section: Clinical Evidencementioning

confidence: 99%

Approaches to stereotactic body radiation therapy for large (≥5 centimeter) non-small cell lung cancer

Verma¹,

Simone²

2018

Transl. Lung Cancer Res

View full text Add to dashboard Cite

Although larger (≥5 cm) node-negative non-small cell lung cancer (NSCLC) lesions are altogether uncommon, their incidence may increase following the implementation of lung cancer screening. A rigorous assessment of stereotactic body radiation therapy (SBRT) for these challenging cases is imperative not only owing to concerns of increased risks when delivering ablative doses to large volumes, but also due to lack of prospective data, as these patients were excluded from seminal phase II SBRT trials. In addition to appraising the available institutional or multi-institutional experiences, multiple strategies to reduce toxicities are discussed. These include exploration of several different dose/fractionation schemes and regimens, as well as specialized techniques for SBRT treatment planning and delivery. Because these lesions have a higher rate of occult lymphatic or distant spread, the role of systemic therapies (including chemotherapy and immunotherapy) are also discussed. Altogether, the publication of several key reports, entirely over the last few years, has created a more solid foundation with which to utilize evidence-based management for this unique patient population.

show abstract

Stereotactic Body Radiotherapy for Large (> 5 cm) Non–Small-Cell Lung Cancer

Abstract: SBRT for tumors > 5 cm is effective, with good local control rates and acceptable toxicity. The main pattern of failure is distant, suggesting a possible role for systemic chemotherapy in these patients.

Cited by 29 publications

References 16 publications

Use of Stereotactic Ablative Radiotherapy (SABR) in Non–Small Cell Lung Cancer Measuring More Than 5 cm

Use of Stereotactic Ablative Radiotherapy (SABR) in Non–Small Cell Lung Cancer Measuring More Than 5 cm

<p>Delicaflavone Reverses Cisplatin Resistance via Endoplasmic Reticulum Stress Signaling Pathway in Non-Small Cell Lung Cancer Cells</p>

Approaches to stereotactic body radiation therapy for large (≥5 centimeter) non-small cell lung cancer

Contact Info

Product

Resources

About